Investor directory

Carisma Therapeutics

Carisma Therapeutics is a clinical-stage biotech company specializing in innovative chimeric antigen receptor macrophage technology to address solid tumors. Its proprietary platform focuses on engineering macrophages and monocytes, a type of myeloid cell, to develop advanced immunotherapies for cancer and other serious diseases. By harnessing the capabilities of these engineered cells, Carisma aims to enhance cellular immunotherapy and improve treatment outcomes for patients with solid tumors. The company's approach enables targeted therapeutic applications, positioning it at the forefront of cancer treatment development.

Top Stages

Acquisition
http://carismatx.com
https://facebook.com/carismather
https://linkedin.com/company/carisma-therapeutics
https://twitter.com/carismather

Jacob Gunterberg

Director

1 past transactions

Sesen Bio

Acquisition in 2022
Sesen Bio, Inc. is a late-stage clinical company focused on developing targeted fusion protein therapeutics for cancer treatment. The company's lead product candidate, Vicinium, is a locally-administered therapy designed for high-risk non-muscle invasive bladder cancer and is currently in phase 3 clinical trials. Another candidate, VB6-845d, aims to treat various EpCAM-positive solid tumors. Additionally, Sesen Bio is exploring combinations of Vicinium with other treatments, including Durvalumab for high-risk non-muscle invasive bladder cancer, and with AstraZeneca's checkpoint inhibitor for squamous cell carcinoma of the head and neck. The company has also partnered with Leiden University Medical Center to co-develop an imaging agent. Founded in 2008 and headquartered in Cambridge, Massachusetts, Sesen Bio was previously known as Eleven Biotherapeutics, Inc. before rebranding in May 2018.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.